Update on systemic treatment in early triple negative breast cancer

被引：29

作者：

Nunez Abad, Martin ^{[1
]}

Calabuig-Farinas, Silvia ^{[2
,4
,5
,6
,7
]}

Lobo de Mena, Miriam ^{[1
]}

Sanz de Bremond, Maria Jose Godes ^{[1
]}

Garcia Gonzalez, Clara ^{[1
]}

Torres Martinez, Susana ^{[2
,4
]}

Angel Garcia-Garcia, Jose ^{[8
]}

Iranzo Gonzalez-Cruz, Vega ^{[1
,2
,3
]}

Camps Herrero, Carlos ^{[1
,2
,4
,6
,7
]}

机构：

[1] Univ Gen Hosp Valencia, Dept Med Oncol, Tres Cruces 2, Valencia 46014, Spain

[2] CIBERONC, Madrid, Spain

[3] Univ Valencia, Dept Med, Valencia, Spain

[4] Univ Gen Hosp Valencia, Gen Univ Hosp Res Fdn, Mol Oncol Lab, Valencia, Spain

[5] Univ Valencia, Dept Pathol, Valencia, Spain

[6] Principe Felipe Res Ctr, Mixed Unit TRIAL, Valencia, Spain

[7] Gen Univ Hosp Valencia Res Fdn, Valencia, Spain

[8] Univ Gen Hosp Valencia, Dept Pathol Anat, Valencia, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷

关键词：

chemotherapy; immunotherapy; neoadjuvant therapy; precision medicine; systemic treatment; triple negative breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; STANDARD NEOADJUVANT CHEMOTHERAPY; SURGICAL ADJUVANT BREAST; PHASE-III TRIAL; OPEN-LABEL; PREOPERATIVE DOXORUBICIN; ANDROGEN RECEPTOR; PROGNOSTIC VALUE; PACLITAXEL; CYCLOPHOSPHAMIDE;

D O I：

10.1177/1758835920986749

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.

引用

页数：18

共 50 条

[41] The Role of Selective Flavonoids on Triple-Negative Breast Cancer: An Update
Chinnikrishnan, Pooja
Ibrahim, Ibrahim Abdel Aziz
Alzahrani, Abdullah R.
Shahzad, Naiyer
Sivaprakasam, Prathibha
Pandurangan, Ashok Kumar
SEPARATIONS, 2023, 10 (03)
[42] Triple-Negative Breast Cancer: Emerging Biomarkers for Early Diagnosis, Prognosis, and Treatment
Roshanizadeh, Zahra
Haghshenas, Mohammad Reza
Ghaderi, Abbas
MIDDLE EAST JOURNAL OF CANCER, 2024, 15 (04) : 257 - 271
[43] TRIPLE-NEGATIVE (TN) TREATMENT APPROACH IN ITALY: AN UPDATE OF NEMESI, A MULTICENTER OBSERVATIONAL STUDY ON EARLY BREAST CANCER (EBC) MANAGEMENT
Adamo, V.
Pronzato, P.
Ricciardi, G. R. R.
Amoroso, D.
Bologna, A.
Lorusso, V.
Simoncini, E.
Testore, F.
Dondi, D.
Clavarezza, M.
ANNALS OF ONCOLOGY, 2010, 21 : 82 - 83
[44] Postneoadjuvant treatment for triple-negative breast cancer
Trapani, Dario
Ferraro, Emanuela
Giugliano, Federica
Bielo, Luca Boscolo
Curigliano, Giuseppe
Burstein, Harold J.
CURRENT OPINION IN ONCOLOGY, 2022, 34 (06) : 623 - 634
[45] Atezolizumab for the treatment of triple-negative breast cancer
Heimes, Anne-Sophie
Schmidt, Marcus
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 1 - 5
[46] Recent treatment progress of triple negative breast cancer
Yang Chang-Qing
Liu Jie
Zhao Shi-Qi
Zhu Kun
Gong Zi-Qian
Xu Ran
Lu Hui-Meng
Zhou Ren-Bin
Zhao Gang
Yin Da-Chuan
Zhang Chen-Yan
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2020, 151 : 40 - 53
[47] Neoadjuvant and adjuvant treatment for triple negative breast cancer
Carey, L.
BREAST, 2021, 56 : S9 - S10
[48] NEW TREATMENT TARGETS FOR TRIPLE NEGATIVE BREAST CANCER
Tutt, A.
Reis-Filho, J. S.
Ashworth, A.
ANNALS OF ONCOLOGY, 2008, 19 : 28 - 28
[49] Treatment Horizons for Triple-negative Breast Cancer
Yeo, W.
HONG KONG JOURNAL OF RADIOLOGY, 2015, 18 (02): : 111 - 118
[50] Local Treatment of Triple-Negative Breast Cancer
Machiels, Melanie
Kaidar-Person, Orit
Rubio, Isabel T.
Poortmans, Philip
CANCER JOURNAL, 2021, 27 (01): : 32 - 40

← 1 2 3 4 5 →